Taken together, these results suggested that anlotinib inhibited the proliferation, migration, and invasion of ICC cells, primarily through the VEGFR2/PI3K/AKT signaling pathway. The gene discussed is AKT1; the disease is intrahepatic cholangiocarcinoma.